Prevention of glucocorticoid-induced osteoporosis.
Patients taking low-dose glucocorticoids for 3 months or more are at risk for rapid bone loss. The loss may be as high as 15% in the first 3 to 6 months of treatment, and can lead to osteoporotic fractures, with an increase in morbidity and mortality. This article discusses an evidence-based approach to the prevention of glucocorticoid-induced osteoporosis.
Saag
Kenneth G
KG
Division of Clinical Immunology and Rheumatology, Center for Education and Research on Therapeutics of Musculoskeletal Disorders, University of Alabama at Birmingham, Birmingham, AL, USA. ksaag@uab.edu
D019386:Alendronate / Q000627:therapeutic use; D000465:Algorithms; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D000068296:Risedronic Acid
D004164:Diphosphonates; D005938:Glucocorticoids; D010281:Parathyroid Hormone; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate